Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

Prior treatment

• Patients currently on antipsychotic treatment with clozapine or any long-acting injectable antipsychotic.

Other illness

• Patient with a diagnosis of schizoaffective disorder, bipolar disorder mental retardation, or other cognitive and neurodevelopmental disorders.
• Patient with a serious and unstable medical condition, forensic patients, or patients with any contraindication mentioned in the SmPC of Risperidone ISM.

Other

• Patient with substance-induced psychosis or psychosis during intoxication (patients with comorbid substance abuse/dependence are allowed).
• Patient unable to answer the study questionnaires.
• Patient who is currently participating in another clinical study.
• Patient pregnant or breast-feeding.

• Patient aged 18 years or older at the time of hospitalisation.
• Patient with diagnosis of schizophrenia, as per clinical judgment.
• Patient admitted to a psychiatric inpatient unit due to an acute exacerbation.
• Patient has started treatment with Risperidone ISM within the previous 48 hours, according to the current Summary of Product Characteristics (SmPC).
• Patient or their legal representative provides written informed consent to participate in the study.